BRISTOL-MYERS SQUIBB COMPANY Equity Method Investment, Realized Gain (Loss) on Disposal
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Equity Method Investment, Realized Gain (Loss) on Disposal of $248.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for the quarter ending 2026-06-30 was $114.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for the quarter ending 2026-03-31 was $134.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for the quarter ending 2025-12-31 was $190.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for the quarter ending 2025-09-30 was $190.00M, a 1483.33% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for fiscal 2025 was $280.00M, a 1650.00% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for fiscal 2024 was $16.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for fiscal 2023 was -$160.00M.
- BRISTOL-MYERS SQUIBB COMPANY equity method investment, realized gain (loss) on disposal for fiscal 2022 was -$801.00M, a 207.52% decline from fiscal 2021.
| Period end | Equity Method Investment, Realized Gain (Loss) on Disposal 3 month | Equity Method Investment, Realized Gain (Loss) on Disposal 6 month | Equity Method Investment, Realized Gain (Loss) on Disposal 9 month | Equity Method Investment, Realized Gain (Loss) on Disposal 12 month |
|---|---|---|---|---|
| 2026-06-30 | $114.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $248.00M 10-Q · filed 2026-07-30 | $438.00M derived: sum of 3 quarters · filed 2026-07-30 | $628.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $134.00M 10-Q · filed 2026-04-30 | $324.00M derived: sum of 2 quarters · filed 2026-04-30 | $514.00M derived: sum of 3 quarters · filed 2026-04-30 | $492.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $190.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $380.00M derived: sum of 2 quarters · filed 2026-02-11 | $358.00M derived: sum of 3 quarters · filed 2026-07-30 | $280.00M 10-K · filed 2026-02-11 |
| 2025-09-30 | $190.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $168.00M derived: sum of 2 quarters · filed 2026-07-30 | $90.00M 10-Q · filed 2025-10-30 | -$115.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$22.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$100.00M 10-Q · filed 2026-07-30 | -$305.00M derived: sum of 3 quarters · filed 2026-07-30 | -$293.00M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$78.00M 10-Q · filed 2026-04-30 | -$283.00M derived: sum of 2 quarters · filed 2026-04-30 | -$271.00M derived: sum of 3 quarters · filed 2026-04-30 | -$164.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$205.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$193.00M derived: sum of 2 quarters · filed 2026-02-11 | -$86.00M derived: sum of 3 quarters · filed 2026-02-11 | $16.00M 10-K · filed 2026-02-11 |
| 2024-09-30 | $12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $119.00M derived: sum of 2 quarters · filed 2025-10-30 | $221.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $107.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $209.00M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $102.00M 10-Q · filed 2025-04-24 | |||
| 2023-12-31 | -$160.00M 10-K · filed 2026-02-11 | |||
| 2022-12-31 | -$801.00M 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $745.00M 10-K · filed 2024-02-13 | |||
| 2020-12-31 | $1.23B 10-K · filed 2023-02-14 | |||
| 2019-12-31 | $275.00M 10-K · filed 2022-02-09 | |||
| 2008-12-31 | $895.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |